Jump to content

Liposomal daunorubicin

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Liposomal daunorubicin (trade name DaunoXome) is a chemotherapy drug that is FDA approved to treat AIDS related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.

See also